Core Viewpoint - Lianhuan Pharmaceutical (600513) is proactively addressing raw material price volatility risks by establishing a comprehensive industrial chain layout, ensuring supply chain security through its subsidiaries and production bases [1] Group 1: Company Strategy - Lianhuan Group, the controlling shareholder of Lianhuan Pharmaceutical, has developed a complete industrial chain layout with intermediate production enterprises such as Inner Mongolia Shengshi Chemical and Prin Pharmaceutical [1] - The company has established two major intermediate production bases in Inner Mongolia and Anhui to secure its supply chain [1] Group 2: Regulatory Compliance and Future Plans - The company’s predecessor, Yangzhou Pharmaceutical Factory, was one of the first in China to pass FDA on-site inspections in 1984 [1] - A new factory is set to pass FDA on-site inspection again in August 2024 [1] - The company plans to leverage its World Health Organization (WHO) pre-certification advantage to enhance the overseas promotion of specialty raw materials like Levonorgestrel, aiming to increase the export sales ratio and make the raw material business a significant growth driver [1]

Macro Highlights - The National Development and Reform Commission, Ministry of Education, and Ministry of Finance have issued a notice to improve the cost-sharing mechanism for preschool education, emphasizing the integration of fee policies with free policies and enhancing service quality [1] - The Ministry of Finance plans to issue a 2025 book-entry discount treasury bond with a total competitive bidding amount of 60 billion yuan, set to be issued at a discount price below face value [1] Market Regulation - The State Administration for Market Regulation has introduced new regulations to enforce food safety responsibilities for food sales chain enterprises, aiming to prevent systemic and regional food safety risks [2] - The Shanghai Gold Exchange has announced measures to strengthen market risk control due to recent volatility in precious metal prices, urging members to enhance risk awareness and maintain market stability [2] Autonomous Driving - Beijing has issued the first batch of L3-level highway autonomous vehicle special license plates, marking a significant milestone in the country's transition to mass production of autonomous vehicles [2][3] - The three vehicles registered for L3-level autonomous driving can operate under specific conditions, achieving a maximum speed of 80 km/h on designated highways [3] Company News - BioShares plans to increase its stake in the company by 50 million to 100 million yuan [4] - Linghuan Pharmaceutical's raw material drug, Levonorgestrel, has passed pre-certification by the World Health Organization [4] - Ningbo Construction's wholly-owned subsidiary has signed a construction contract worth 428 million yuan [4] - Yingstone Innovation has launched its Yingling A1 panoramic drone in select regional markets [4] - Zongjie Automotive has secured a new project for electric air conditioning compressor scroll plates from an international client [4] - Haizheng Pharmaceutical's subsidiary has received approval for a veterinary drug product [4] - Xinhua Pharmaceutical has obtained a drug registration certificate for Oseltamivir phosphate dry suspension [4] - *ST Songfa's subsidiary has signed contracts for the construction of eight vessels [4] - Kuangda Technology plans to establish a subsidiary in Zhuzhou as a core business hub in Central China [4] - BOE Technology Group's subsidiary has passed the listing guidance acceptance at the Beijing Stock Exchange [4] - Xiangpiaopiao intends to set up an overseas subsidiary and build a production base in Thailand [4] - Zhengdan Co. has begun trial production of a nitrogen project utilizing exhaust gas [4] - Yuanda Pharmaceutical has introduced the world's first epinephrine nasal spray for severe allergic reactions [4] - Bertley is planning to issue H-shares and list on the Hong Kong Stock Exchange [4] - Baoshan Co. has won a contract worth approximately 1.2 billion yuan for a power cable project from the Singapore Power Authority [4]

Policy Developments - The National Healthcare Security Administration is soliciting public opinions on the "Traditional Chinese Medicine Decoction Pieces Traceability Code Encoding Rules" to promote a unified traceability system for traditional Chinese medicine [1] - The National Medical Products Administration has released the "Internet Drug and Medical Device Information Service Filing Management Regulations," which will take effect immediately [2] Drug and Device Approvals - YHLO Biotech announced that it has received medical device registration certificates for two products from the Guangdong and Hunan Provincial Medical Products Administration [3] - Lianhuan Pharmaceutical reported that its raw material drug, Levonorgestrel, has passed pre-certification by the World Health Organization, although this will not significantly impact current operating performance [4] Capital Market Activities - Taiji Group plans to publicly transfer 40% of its stake in the subsidiary company Aida through a public listing, with an initial transfer price of 108,000 yuan [5] - Jiangsu Zhiyuan Pharmaceutical has completed nearly 300 million yuan in Pre-IPO financing, led by Innovation Works [6] Industry Developments - Tongxin Medical announced that its fully magnetic levitation artificial heart has completed enrollment of 100 patients in the INNOVATE clinical trial in the U.S. [7][8] - Novo Nordisk plans to launch the oral version of Wegovy in the U.S. in January 2026, marking it as the first oral GLP-1 drug for weight management [9] Public Sentiment - The Zhejiang Provincial Government has dispatched a working group to oversee the follow-up handling of a medical incident involving a child's postoperative death at Ningbo University Women's and Children's Hospital [10] Regulatory Actions - Haohai Biological Technology announced that its controlling shareholder, Jiang Wei, has been fined 14.63 million yuan by the China Securities Regulatory Commission for insider trading, which will not affect the company's daily operations [11]

Core Viewpoint - The company, Lianhuan Pharmaceutical (600513.SH), has received notification from the World Health Organization (WHO) that its active pharmaceutical ingredient, Levonorgestrel (APIMF484, WHO API-484), has passed the WHO prequalification (PQ) process and is now included in the procurement scope of international organizations and public institutions [1] Group 1 - The product has successfully passed the WHO prequalification site inspection [1] - As of the date of this announcement, the Drug Master File (DMF) review for the product has also been completed [1] - The product is now fully prequalified by the WHO [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, has received notification from the World Health Organization (WHO) that its raw material drug, Levonorgestrel, has passed the WHO prequalification, allowing it to be included in procurement by international organizations and public institutions [1] Group 1 - The company announced that its Levonorgestrel product is now recognized by the WHO, expanding its market potential [1] - The company's subsidiary, Changle Pharmaceutical, has received approval from the National Medical Products Administration for a supplemental application regarding Atropine Sulfate Injection, which includes the addition of a new specification of 1ml: 0.5mg [1] - The approval also pertains to the consistency evaluation of the quality and efficacy of the generic drug [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, has received notification from the World Health Organization (WHO) that its active pharmaceutical ingredient, Levonorgestrel, has passed the WHO prequalification process [1] Group 1: WHO Prequalification - The product Levonorgestrel has successfully undergone on-site inspection and the Drug Master File (DMF) review by the WHO, achieving full prequalification [1] - This prequalification is expected to enhance the company's credibility in the global market [1] Group 2: Financial Impact - The prequalification is not anticipated to have a significant impact on the company's current operating performance [1] - Future sales orders for the product remain uncertain, indicating potential variability in revenue generation [1]

Core Points - The company received notification from the World Health Organization (WHO) regarding the successful closure of the on-site inspection for its active pharmaceutical ingredient, Levonorgestrel (APIMF484, WHOAPI-484) [1] - The inspection results indicate that the company's production line complies with WHO Good Manufacturing Practice (GMP) standards, which is beneficial for maintaining stable product quality and production capacity to meet market demand [1] - The successful WHO pre-certification inspection is not expected to have a significant impact on the company's recent performance [1]

Core Viewpoint - The company received notification from the World Health Organization that its raw material drug product, Levonorgestrel, has passed the site inspection, meeting the WHO's good manufacturing practice standards [1] Group 1: Inspection Details - The inspection took place from March 10 to March 13, 2025, covering the synthesis area and part of the cleanroom production lines [1] - The successful inspection is expected to help maintain product quality and production capacity [1] Group 2: Financial Impact - The inspection results are not expected to have a significant impact on the company's recent performance [1] - The drug master file review has not been closed, indicating uncertainty regarding future procurement [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, has successfully passed the World Health Organization's (WHO) pre-certification inspection for its active pharmaceutical ingredient, Levonorgestrel, indicating compliance with Good Manufacturing Practice (GMP) standards [1] Group 1: Company Performance - The successful completion of the WHO inspection demonstrates that the company's production line meets GMP requirements, which is crucial for maintaining stable product quality [1] - The inspection results are expected to support the company's ability to sustain stable production capacity to meet market demand for related pharmaceuticals [1] Group 2: Market Impact - The passing of the WHO pre-certification inspection is not anticipated to have a significant impact on the company's recent performance [1]

Group 1: Company Overview and Product Development - The company focuses on innovative drugs primarily in cardiovascular, urology, oncology, and respiratory systems, with 6 innovative drugs in development, including 1 in Phase III, 2 in Phase I, and 3 in preclinical research [2] - The product Aipulete has shown strong market performance, with projected sales of 119 million tablets in 2024, representing a 30.28% increase from the previous year [2] - The company emphasizes innovation-driven development strategies, enhancing R&D platforms, increasing investment in technology innovation, and promoting digital transformation and sustainable development [2] Group 2: Export Strategy and International Development - The company primarily exports raw materials to markets in North America, Eastern Europe, Southeast Asia, South America, and Oceania [3] - The company established Unioncle Pharma LLC in the U.S. in 2023 to facilitate international collaboration and accelerate the internationalization of its R&D products [3] - The company is actively seeking opportunities for its newly developed raw materials through various channels to enhance its global presence [3] Group 3: Strategic Acquisitions - The company acquired Longyi Pharmaceutical to strengthen its market presence in Southwest China, aiming to create a dual-core driving pattern with its headquarters in the Yangtze River Delta [4] - Longyi Pharmaceutical has a dense distribution network and advantages in the outpatient market, which will accelerate the regional penetration of the company's existing products [4] - The company's national sales system will provide Longyi Pharmaceutical with more upstream pharmaceutical cooperation resources, expanding its wholesale categories [4]